58 results on '"Jonathan R Dry"'
Search Results
2. Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling
3. Network-driven cancer cell avatars for combination discovery and biomarker identification for DNA damage response inhibitors
4. Author Correction: Network-driven cancer cell avatars for combination discovery and biomarker identification for DNA damage response inhibitors
5. The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells
6. Privacy preserving validation for multiomic prediction models.
7. Contrived Materials and a Data Set for the Evaluation of Liquid Biopsy Tests
8. Supplementary Figures 1-5 from AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies
9. supplementary Table 2 from Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547
10. Supplementary Table 3 from AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies
11. Supplementary figures from Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547
12. supplementary Table1 from Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547
13. Supplementary Table 1 from AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies
14. Data from Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547
15. supplementary Table 3 from Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547
16. supplementary Table 4 from Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547
17. supplementary figure and table legend from Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547
18. Data from AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies
19. supplementary Table 6 from Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547
20. supplementary Table 5 from Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547
21. Supplementary Table 2 from AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies
22. Supplementary Figures from Pharmacological Inhibition of PARP6 Triggers Multipolar Spindle Formation and Elicits Therapeutic Effects in Breast Cancer
23. Data from PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models
24. Data from Clinically Viable Gene Expression Assays with Potential for Predicting Benefit from MEK Inhibitors
25. Data from Pharmacological Inhibition of PARP6 Triggers Multipolar Spindle Formation and Elicits Therapeutic Effects in Breast Cancer
26. S1 from PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models
27. Supplemental Tables S1 to S4 and Figures S1 to S5 including legends and footnotes from Clinically Viable Gene Expression Assays with Potential for Predicting Benefit from MEK Inhibitors
28. Supplemental Materials from Pharmacological Inhibition of PARP6 Triggers Multipolar Spindle Formation and Elicits Therapeutic Effects in Breast Cancer
29. Supplementary Table 7 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
30. Supplementary Table 1 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
31. Supplementary Table 3 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
32. Supplementary Table 5 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
33. Supplementary Table 6 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
34. Supplementary Figures S1-S6 from Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models
35. Supplementary Methods and References from Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models
36. Supplementary Figures 8-12 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
37. Supplementary Figure 5 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
38. Supplementary Table 4 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
39. Supplementary Figure 1 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
40. Supplementary Table 2 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
41. Supplementary Figure Legend from Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models
42. Supplementary Figure 2 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
43. Data from Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models
44. Supplementary Figure 4 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
45. Supplementary References from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
46. Supplementary Tables S1-S4 from Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models
47. Supplementary Figure 6 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
48. Supplementary Figure 7 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
49. Supplementary Figure 3 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
50. Supplementary Table and Figure Legends from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.